Combining vanadyl sulfate with Newcastle disease virus potentiates rapid innate immune-mediated regression with curative potential in murine cancer models.
B16-F10
Newcastle disease virus (NDV)
combination therapy
vanadyl sulfate
Journal
Molecular therapy oncolytics
ISSN: 2372-7705
Titre abrégé: Mol Ther Oncolytics
Pays: United States
ID NLM: 101666776
Informations de publication
Date de publication:
26 Mar 2021
26 Mar 2021
Historique:
received:
08
01
2021
accepted:
16
01
2021
entrez:
22
2
2021
pubmed:
23
2
2021
medline:
23
2
2021
Statut:
epublish
Résumé
The avian paramyxovirus, Newcastle disease virus (NDV), is a promising oncolytic agent that has been shown to be safe and effective in a variety of pre-clinical cancer models and human clinical trials. NDV preferentially replicates in tumor cells due to signaling defects in apoptotic and antiviral pathways acquired during the transformation process and is a potent immunostimulatory agent. However, when used as a monotherapy NDV lacks the ability to consistently generate durable remissions. Here we investigate the use of viral sensitizer-mediated combination therapy to enhance the anti-neoplastic efficacy of NDV. Intratumoral injection of vanadyl sulfate, a pan-inhibitor of protein tyrosine phosphatases, in combination with NDV significantly increased the number and activation status of natural killer (NK) cells in the tumor microenvironment, concomitant with increased expression of interferon-β, granulocyte-macrophage colony-stimulating factor, and monocyte chemoattractant protein-1, leading to rapid tumor regression and long-term cures in mice bearing syngeneic B16-F10 melanomas. The anti-tumor efficacy of this combination therapy was abrogated when NK cells were depleted and when interferon-β expression was transiently suppressed. Tumor-specific CD8
Identifiants
pubmed: 33614913
doi: 10.1016/j.omto.2021.01.009
pii: S2372-7705(21)00010-3
pmc: PMC7868934
doi:
Types de publication
Journal Article
Langues
eng
Pagination
306-324Informations de copyright
© 2021 The Author(s).
Déclaration de conflit d'intérêts
J.S.D. is an inventor on a patent describing the use of vanadium compounds as enhancers of oncolytic virotherapy. This patent (publication #20190231832) is licensed to Virica Biotech, where J.S.D. is co-founder and serves as an executive.
Références
J Clin Invest. 1995 Jun;95(6):2501-9
pubmed: 7769096
Mol Ther Methods Clin Dev. 2017 Oct 16;9:181-191
pubmed: 29556508
Immunology. 1999 May;97(1):159-65
pubmed: 10447727
Immunity. 1998 Nov;9(5):669-76
pubmed: 9846488
Methods Mol Biol. 2011;740:27-32
pubmed: 21468965
Clin Cancer Res. 2001 Jun;7(6):1821-31
pubmed: 11410525
Mol Ther. 2011 Jun;19(6):1008-16
pubmed: 21505424
Nat Rev Drug Discov. 2015 Sep;14(9):642-62
pubmed: 26323545
Mol Ther. 2018 Jan 3;26(1):56-69
pubmed: 29175158
Clin Exp Immunol. 1989 Mar;75(3):376-80
pubmed: 2784743
Nat Commun. 2017 Feb 13;8:14340
pubmed: 28194010
Mol Ther. 2010 Feb;18(2):275-84
pubmed: 19809404
J Immunol. 2007 Jun 15;178(12):7540-9
pubmed: 17548588
Future Microbiol. 2012 Mar;7(3):347-67
pubmed: 22393889
Cancer Res. 2007 Sep 1;67(17):8285-92
pubmed: 17804743
Proc Natl Acad Sci U S A. 2007 Jun 5;104(23):9788-93
pubmed: 17535926
Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):734-9
pubmed: 10639148
Arch Toxicol. 2004 Jan;78(1):7-15
pubmed: 13680095
J Appl Toxicol. 2019 Mar;39(3):540-552
pubmed: 30407648
Mol Ther. 2006 Sep;14(3):361-70
pubmed: 16905462
Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14981-6
pubmed: 18815361
Microbiol Immunol. 1984;28(1):75-83
pubmed: 6563380
Cancer Biol Med. 2017 Aug;14(3):228-241
pubmed: 28884040
Annu Rev Immunol. 2013;31:563-604
pubmed: 23516985
Mol Cell Biochem. 1995 Dec 6-20;153(1-2):17-24
pubmed: 8927035
Cancers (Basel). 2020 Nov 28;12(12):
pubmed: 33260685
Biologics. 2008 Mar;2(1):13-27
pubmed: 19707424
Cancer Res. 2009 Oct 1;69(19):7713-20
pubmed: 19773437
Mol Ther Methods Clin Dev. 2019 Jan 29;13:154-166
pubmed: 30788384
Front Immunol. 2016 Oct 07;7:414
pubmed: 27774094
Cancers (Basel). 2018 Jun 26;10(7):
pubmed: 29949934
J Virol. 2006 Aug;80(15):7522-34
pubmed: 16840332
Mol Cell Biochem. 1995 Dec 6-20;153(1-2):49-58
pubmed: 8927047
Mol Ther. 2019 Jun 5;27(6):1139-1152
pubmed: 31053413
Cell. 1996 Sep 6;86(5):787-98
pubmed: 8797825
Br J Cancer. 2016 Feb 16;114(4):357-61
pubmed: 26766734
Cancer Res. 2012 Aug 1;72(15):3735-43
pubmed: 22593190
Metallomics. 2019 Oct 16;11(10):1687-1699
pubmed: 31490510
Pediatr Pulmonol. 2002 Aug;34(2):128-30
pubmed: 12112779
J Virol. 2020 Jan 17;94(3):
pubmed: 31694938
PLoS Med. 2007 Dec;4(12):e353
pubmed: 18162040
Clin Cancer Res. 1996 Jan;2(1):21-8
pubmed: 9816085
Curr Pharm Biotechnol. 2012 Jul;13(9):1817-33
pubmed: 21740354
J Biol Chem. 1990 Feb 15;265(5):2896-902
pubmed: 2154464
PLoS One. 2014 Aug 13;9(8):e104698
pubmed: 25119105
Mol Ther. 2014 Feb;22(2):420-429
pubmed: 24322333
Cell. 1989 Mar 24;56(6):917-30
pubmed: 2538247
Front Immunol. 2019 Feb 12;10:9
pubmed: 30809220
Mol Ther. 2009 Apr;17(4):697-706
pubmed: 19209145
Sci Transl Med. 2014 Mar 5;6(226):226ra32
pubmed: 24598590
Immunology. 2020 Feb;159(2):167-177
pubmed: 31646612
EBioMedicine. 2019 Nov;49:96-105
pubmed: 31676387
Mol Ther Oncolytics. 2014 Dec 10;1:14004
pubmed: 27119094
Mol Ther. 2010 Jun;18(6):1123-9
pubmed: 20389287
Cytokine. 2012 Sep;59(3):467-78
pubmed: 22704694
Front Immunol. 2017 Mar 31;8:304
pubmed: 28408907
Vet Med Int. 2012;2012:708216
pubmed: 22577610
Gene Ther. 2008 Mar;15(5):371-83
pubmed: 18200068
Adv Exp Med Biol. 2010;684:28-41
pubmed: 20795538
Cancer Gene Ther. 2010 Aug;17(8):550-8
pubmed: 20379224
Int J Cancer. 2006 Jul 15;119(2):328-38
pubmed: 16470838
J Natl Cancer Inst. 1992 Aug 5;84(15):1185-90
pubmed: 1378904
Sci Transl Med. 2018 Jan 24;10(425):
pubmed: 29367345
Int J Cancer. 2019 Aug 15;145(4):974-978
pubmed: 30694555
Int J Cancer. 1989 Mar 15;43(3):526-30
pubmed: 2494120
J Virol. 2010 Jul;84(13):6687-98
pubmed: 20410284
Gene Ther. 2007 Dec;14(23):1639-49
pubmed: 17914407
Expert Opin Biol Ther. 2020 Jun;20(6):635-652
pubmed: 32067509
Gene Ther. 2015 Dec;22(12):947-59
pubmed: 26196249
Toxicol Appl Pharmacol. 1996 May;138(1):1-11
pubmed: 8658498
PLoS One. 2014 Mar 17;9(3):e91126
pubmed: 24637385
Immunity. 2007 Apr;26(4):503-17
pubmed: 17398124
Oxid Med Cell Longev. 2016;2016:4013639
pubmed: 27190573
Nat Commun. 2015 Mar 30;6:6410
pubmed: 25817275
Vet Immunol Immunopathol. 2005 Mar 10;104(1-2):33-44
pubmed: 15661329
Cell. 2017 Sep 7;170(6):1109-1119.e10
pubmed: 28886381
Virus Res. 2017 Apr 2;233:35-41
pubmed: 28286036
PLoS One. 2011;6(10):e26264
pubmed: 22022583
Cancer Gene Ther. 2005 Apr;12(4):359-68
pubmed: 15678154
J Virol. 2006 Jun;80(11):5145-55
pubmed: 16698995
Nat Rev Immunol. 2011 Aug 26;11(10):645-57
pubmed: 21869816
J Immunol. 1978 Jul;121(1):304-9
pubmed: 307576
Mutat Res. 1996 Feb 29;359(2):77-84
pubmed: 8598834
Proc Natl Acad Sci U S A. 2013 Feb 5;110(6):2252-7
pubmed: 23345426
PLoS Pathog. 2011 Aug;7(8):e1002141
pubmed: 21829360
World J Virol. 2016 May 12;5(2):85-6
pubmed: 27175354
J Virol. 2011 Jun;85(12):6015-23
pubmed: 21471241
J Immunol. 2002 Oct 15;169(8):4279-87
pubmed: 12370359
J Immunol. 2000 Oct 1;165(7):3571-7
pubmed: 11034357
Mol Ther Oncolytics. 2019 Nov 02;15:234-247
pubmed: 31872046
Trends Mol Med. 2004 May;10(5):210-6
pubmed: 15121047
Sci Rep. 2016 May 26;6:26786
pubmed: 27226390
Mol Ther. 2003 Jun;7(6):755-64
pubmed: 12788649